BioCentury | Apr 3, 2020
Deals

Servier adds mAb platform via takeout of former European biotech darling Symphogen

What was once a high-profile European biotech is now going out quietly as Servier is acquiring Danish mAb company Symphogen A/S for an undisclosed sum. The two companies are partnered across three clinical stage immuno-oncology...
BioCentury | Oct 6, 2017
Clinical News

Symphogen's Sym004 misses in Phase II for mCRC

Symphogen A/S (Copenhagen, Denmark) reported data from a Phase II trial in 254 patients with advanced metastatic colorectal cancer (mCRC) and acquired resistance to marketed anti-EGFR mAbs showing that low- and high-dose IV Sym004 each...
BioCentury | Oct 23, 2015
Financial News

Symphogen raises EUR 67.5M in convertible debt

Symphogen A/S (Copenhagen, Denmark) raised EUR 67.5 million ($76.6 million) in convertible debt led by existing investors Novo A/S and Danish pension fund PKA . Existing investors including pension fund Danica; Essex Woodlands; and Sunstone Capital...
BioCentury | Feb 2, 2015
Company News

Symphogen, Merck KGaA deal

Symphogen regained rights from Merck to Sym004 . Merck said it decided to return rights after an analysis of its pipeline assets, and both companies said that the decision was not related to any new safety...
BioCentury | Jan 30, 2015
Company News

Merck KGaA returns Sym004 rights to Symphogen

Symphogen A/S (Copenhagen, Denmark) regained exclusive, worldwide rights to Sym004 from Merck KGaA (Xetra:MRK), unwinding a 2012 deal. Both Merck and Symphogen said the decision was not related to new safety or efficacy results related...
BioCentury | Aug 18, 2014
Clinical News

Sym004: Phase Ib started

Symphogen said Merck began a 2-part, open-label, international Phase Ib trial of IV Sym004 in combination with platinum-doublets in about 89 patients with stage IV NSCLC. The first part will evaluate escalating doses of 6-18...
BioCentury | Aug 18, 2014
Clinical News

Sym004: Phase IIb started

Symphogen said Merck began an open-label, international Phase IIb trial to compare IV Sym004 vs. investigator’s choice of best supportive care (BSC) in about 240 patients with mCRC and acquired resistance to marketed anti-EGFR mAbs....
BioCentury | May 26, 2014
Finance

Europe's Iceberg 2014: Premier League teams

Competing in biotech's Premier League requires deep pockets, long term planning and the risk appetite to pursue novel technologies or targets that don't always pan out. BioCentury's 12th annual European Iceberg survey reveals that for...
BioCentury | Jul 15, 2013
Company News

Symphogen, Merck KGaA deal

Symphogen received an undisclosed milestone payment from Merck under a September 2012 deal granting Merck exclusive, worldwide rights to develop and commercialize cancer product Sym004 . The payment was triggered by an undisclosed drug development milestone...
BioCentury | Jun 24, 2013
Clinical News

Sym004: Additional Phase I/II data

Data from 39 evaluable patients with wild-type K-Ras refractory or recurrent advanced metastatic colorectal cancer (mCRC) in Part B and C of an open-label, dose-escalation, international Phase I/II trial showed that once-weekly IV Sym004 led...
Items per page:
1 - 10 of 30